Pediatric phase II cancer chemotherapy trials: A Pediatric Oncology Group study

Steven Weitman, Stephanie Ochoa, James Sullivan, Jonathan Shuster, Naomi Winick, Charles Pratt, Teresa Vietti, Michael Harris

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Purpose: This study reviewed the Pediatric Oncology Group experience with phase II clinical trials in children (<21 years of age) with refractory tumors. Patients and Methods: Patients registered in Pediatric Oncology Group phase II studies were evaluated. Patients had to be <21 years of age with recurrent and refractory measurable disease. Tumor types and response rates were determined. Death on therapy from either drug toxicity, progressive disease, infection, or hemorrhage was measured. Tumor-specific, disease-free survival curves were calculated by Kaplan-Meier analysis. Results: Between 1984 and 1994, 2,465 patient entries were made on 45 phase II trials. Malignancies registered included acute lymphocytic leukemia (ALL) (16.7%), acute myeloid leukemia (AML) (12.0%), osteogenic sarcoma (7.8%), neuroblastoma (7.2%), astrocytoma (7.2%), medulloblastoma (7.1%), glioma (6.7%), ependymoma (6.1%), and others (29.2%). The overall response rate was 19.6% (CR + PR) for children entered on phase II trials. Tumor-specific response rates ranged from 62.1% (23/37) for children with Hodgkin's disease to no responses (0/23) in patients with hepatoblastoma. When comparing single versus multiagent trials, a significantly better initial response rate was seen in the latter studies. However, 5-year survival was comparable. Progression free survival for all tumor histologies were 12.9% and 9.2% at 2 and 5 years, respectively. Death on study was seen in 11.6% of the patients; however, only three deaths were directly related to drug toxicity. There were no significant gender differences in regards to response, progressive disease, or death on study. Conclusion: Phase II studies conducted in children offer a considerable likelihood of therapeutic benefit without exposing these patients to untoward toxicity.

Original languageEnglish (US)
Pages (from-to)187-191
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume19
Issue number3
DOIs
StatePublished - May 1997

Fingerprint

Pediatrics
Drug Therapy
Neoplasms
Drug-Related Side Effects and Adverse Reactions
Disease-Free Survival
Hepatoblastoma
Ependymoma
Phase II Clinical Trials
Medulloblastoma
Astrocytoma
Kaplan-Meier Estimate
Osteosarcoma
Hodgkin Disease
Neuroblastoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Glioma
Histology
Hemorrhage
Survival

Keywords

  • Cancer
  • Chemotherapy
  • Pediatric oncology
  • Phase II trials

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Pediatric phase II cancer chemotherapy trials : A Pediatric Oncology Group study. / Weitman, Steven; Ochoa, Stephanie; Sullivan, James; Shuster, Jonathan; Winick, Naomi; Pratt, Charles; Vietti, Teresa; Harris, Michael.

In: Journal of Pediatric Hematology/Oncology, Vol. 19, No. 3, 05.1997, p. 187-191.

Research output: Contribution to journalArticle

Weitman, S, Ochoa, S, Sullivan, J, Shuster, J, Winick, N, Pratt, C, Vietti, T & Harris, M 1997, 'Pediatric phase II cancer chemotherapy trials: A Pediatric Oncology Group study', Journal of Pediatric Hematology/Oncology, vol. 19, no. 3, pp. 187-191. https://doi.org/10.1097/00043426-199705000-00002
Weitman, Steven ; Ochoa, Stephanie ; Sullivan, James ; Shuster, Jonathan ; Winick, Naomi ; Pratt, Charles ; Vietti, Teresa ; Harris, Michael. / Pediatric phase II cancer chemotherapy trials : A Pediatric Oncology Group study. In: Journal of Pediatric Hematology/Oncology. 1997 ; Vol. 19, No. 3. pp. 187-191.
@article{349850b5ad5f433084b7d3786bb2a358,
title = "Pediatric phase II cancer chemotherapy trials: A Pediatric Oncology Group study",
abstract = "Purpose: This study reviewed the Pediatric Oncology Group experience with phase II clinical trials in children (<21 years of age) with refractory tumors. Patients and Methods: Patients registered in Pediatric Oncology Group phase II studies were evaluated. Patients had to be <21 years of age with recurrent and refractory measurable disease. Tumor types and response rates were determined. Death on therapy from either drug toxicity, progressive disease, infection, or hemorrhage was measured. Tumor-specific, disease-free survival curves were calculated by Kaplan-Meier analysis. Results: Between 1984 and 1994, 2,465 patient entries were made on 45 phase II trials. Malignancies registered included acute lymphocytic leukemia (ALL) (16.7{\%}), acute myeloid leukemia (AML) (12.0{\%}), osteogenic sarcoma (7.8{\%}), neuroblastoma (7.2{\%}), astrocytoma (7.2{\%}), medulloblastoma (7.1{\%}), glioma (6.7{\%}), ependymoma (6.1{\%}), and others (29.2{\%}). The overall response rate was 19.6{\%} (CR + PR) for children entered on phase II trials. Tumor-specific response rates ranged from 62.1{\%} (23/37) for children with Hodgkin's disease to no responses (0/23) in patients with hepatoblastoma. When comparing single versus multiagent trials, a significantly better initial response rate was seen in the latter studies. However, 5-year survival was comparable. Progression free survival for all tumor histologies were 12.9{\%} and 9.2{\%} at 2 and 5 years, respectively. Death on study was seen in 11.6{\%} of the patients; however, only three deaths were directly related to drug toxicity. There were no significant gender differences in regards to response, progressive disease, or death on study. Conclusion: Phase II studies conducted in children offer a considerable likelihood of therapeutic benefit without exposing these patients to untoward toxicity.",
keywords = "Cancer, Chemotherapy, Pediatric oncology, Phase II trials",
author = "Steven Weitman and Stephanie Ochoa and James Sullivan and Jonathan Shuster and Naomi Winick and Charles Pratt and Teresa Vietti and Michael Harris",
year = "1997",
month = "5",
doi = "10.1097/00043426-199705000-00002",
language = "English (US)",
volume = "19",
pages = "187--191",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Pediatric phase II cancer chemotherapy trials

T2 - A Pediatric Oncology Group study

AU - Weitman, Steven

AU - Ochoa, Stephanie

AU - Sullivan, James

AU - Shuster, Jonathan

AU - Winick, Naomi

AU - Pratt, Charles

AU - Vietti, Teresa

AU - Harris, Michael

PY - 1997/5

Y1 - 1997/5

N2 - Purpose: This study reviewed the Pediatric Oncology Group experience with phase II clinical trials in children (<21 years of age) with refractory tumors. Patients and Methods: Patients registered in Pediatric Oncology Group phase II studies were evaluated. Patients had to be <21 years of age with recurrent and refractory measurable disease. Tumor types and response rates were determined. Death on therapy from either drug toxicity, progressive disease, infection, or hemorrhage was measured. Tumor-specific, disease-free survival curves were calculated by Kaplan-Meier analysis. Results: Between 1984 and 1994, 2,465 patient entries were made on 45 phase II trials. Malignancies registered included acute lymphocytic leukemia (ALL) (16.7%), acute myeloid leukemia (AML) (12.0%), osteogenic sarcoma (7.8%), neuroblastoma (7.2%), astrocytoma (7.2%), medulloblastoma (7.1%), glioma (6.7%), ependymoma (6.1%), and others (29.2%). The overall response rate was 19.6% (CR + PR) for children entered on phase II trials. Tumor-specific response rates ranged from 62.1% (23/37) for children with Hodgkin's disease to no responses (0/23) in patients with hepatoblastoma. When comparing single versus multiagent trials, a significantly better initial response rate was seen in the latter studies. However, 5-year survival was comparable. Progression free survival for all tumor histologies were 12.9% and 9.2% at 2 and 5 years, respectively. Death on study was seen in 11.6% of the patients; however, only three deaths were directly related to drug toxicity. There were no significant gender differences in regards to response, progressive disease, or death on study. Conclusion: Phase II studies conducted in children offer a considerable likelihood of therapeutic benefit without exposing these patients to untoward toxicity.

AB - Purpose: This study reviewed the Pediatric Oncology Group experience with phase II clinical trials in children (<21 years of age) with refractory tumors. Patients and Methods: Patients registered in Pediatric Oncology Group phase II studies were evaluated. Patients had to be <21 years of age with recurrent and refractory measurable disease. Tumor types and response rates were determined. Death on therapy from either drug toxicity, progressive disease, infection, or hemorrhage was measured. Tumor-specific, disease-free survival curves were calculated by Kaplan-Meier analysis. Results: Between 1984 and 1994, 2,465 patient entries were made on 45 phase II trials. Malignancies registered included acute lymphocytic leukemia (ALL) (16.7%), acute myeloid leukemia (AML) (12.0%), osteogenic sarcoma (7.8%), neuroblastoma (7.2%), astrocytoma (7.2%), medulloblastoma (7.1%), glioma (6.7%), ependymoma (6.1%), and others (29.2%). The overall response rate was 19.6% (CR + PR) for children entered on phase II trials. Tumor-specific response rates ranged from 62.1% (23/37) for children with Hodgkin's disease to no responses (0/23) in patients with hepatoblastoma. When comparing single versus multiagent trials, a significantly better initial response rate was seen in the latter studies. However, 5-year survival was comparable. Progression free survival for all tumor histologies were 12.9% and 9.2% at 2 and 5 years, respectively. Death on study was seen in 11.6% of the patients; however, only three deaths were directly related to drug toxicity. There were no significant gender differences in regards to response, progressive disease, or death on study. Conclusion: Phase II studies conducted in children offer a considerable likelihood of therapeutic benefit without exposing these patients to untoward toxicity.

KW - Cancer

KW - Chemotherapy

KW - Pediatric oncology

KW - Phase II trials

UR - http://www.scopus.com/inward/record.url?scp=0030920199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030920199&partnerID=8YFLogxK

U2 - 10.1097/00043426-199705000-00002

DO - 10.1097/00043426-199705000-00002

M3 - Article

C2 - 9201138

AN - SCOPUS:0030920199

VL - 19

SP - 187

EP - 191

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 3

ER -